Claims for Patent: 7,989,474
✉ Email this page to a colleague
Summary for Patent: 7,989,474
| Title: | Use of Lck inhibitors for treatment of immunologic diseases |
| Abstract: | The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component. |
| Inventor(s): | Roth; Gerald Juergen (Biberach, DE), Heckel; Armin (Biberach, DE), Walter; Rainer (Biberach, DE), Hilberg; Frank (Vienna, AT), Hauptmann; Rudolf (Ebreichsdorf, AT), Stefanic; Martin Fredrich (Warthausen-Birkenhard, DE), Colbatzky; Florian (Stafflangen, DE), Ernest; Steffan (Moelnlycke, SE) |
| Assignee: | Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE) |
| Application Number: | 12/334,323 |
| Patent Claims: |
1. A method for treating lung fibrosis comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising
(Z)-3-(1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)- -phenylamino)-1-phenyl-methylene)-6-methoxycarbonyl-2-indolinone or a tautomer, stereoisomer or physiologically acceptable salt thereof.
2. The method according to claim 1, wherein the pharmaceutical composition is administered orally, parenterally, or rectally. |
